Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus
Ioannis Parodis, Christopher Sjöwall, Andreas Jönsen, et al.
Autoimmunity Reviews (2017) Vol. 16, Iss. 4, pp. 343-351
Closed Access | Times Cited: 96

Showing 1-25 of 96 citing articles:

2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis
Antonis Fanouriakis, Myrto Kostopoulou, Kim Cheema, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 6, pp. 713-723
Open Access | Times Cited: 654
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Antonis Fanouriakis, Myrto Kostopoulou, Jeanette Andersen, et al.
Annals of the Rheumatic Diseases (2023) Vol. 83, Iss. 1, pp. 15-29
Open Access | Times Cited: 368
Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options
Eve Smith, Hanna Lythgoe, Angela Midgley, et al.
Clinical Immunology (2019) Vol. 209, pp. 108274-108274
Closed Access | Times Cited: 152
Targeted Immunotherapy for Autoimmune Disease
Seung Min Jung, Wan‐Uk Kim
Immune Network (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 109
EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis
Ioannis Parodis, Charlotte Girard, Laurent Arnaud, et al.
Annals of the Rheumatic Diseases (2023) Vol. 83, Iss. 6, pp. 720-729
Open Access | Times Cited: 55
Cardiovascular disease in systemic lupus erythematosus: A comprehensive update
Mayra Giannelou, Clio P. Mavragani
Journal of Autoimmunity (2017) Vol. 82, pp. 1-12
Closed Access | Times Cited: 163
Belimumab: A Review in Systemic Lupus Erythematosus
Hannah A. Blair, Sean T. Duggan
Drugs (2018) Vol. 78, Iss. 3, pp. 355-366
Closed Access | Times Cited: 135
Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors
Laurent Arnaud, Maria G. Tektonidou
Lara D. Veeken (2020) Vol. 59, Iss. Supplement_5, pp. v29-v38
Open Access | Times Cited: 128
B cell alterations during BAFF inhibition with belimumab in SLE
Daniel Ramsköld, Ioannis Parodis, Tadepally Lakshmikanth, et al.
EBioMedicine (2018) Vol. 40, pp. 517-527
Open Access | Times Cited: 111
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real‐Life Setting
Mariele Gatto, Francesca Saccon, Margherita Zen, et al.
Arthritis & Rheumatology (2020) Vol. 72, Iss. 8, pp. 1314-1324
Open Access | Times Cited: 95
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study
Luca Iaccarino, Laura Andréoli, Elena Bartoloni, et al.
Journal of Autoimmunity (2017) Vol. 86, pp. 1-8
Closed Access | Times Cited: 94
Cardiovascular Disease in Systemic Lupus Erythematosus: Recent Data on Epidemiology, Risk Factors and Prevention
Myrto Kostopoulou, Dionysis Nikolopoulos, Ioannis Parodis, et al.
Current Vascular Pharmacology (2019) Vol. 18, Iss. 6, pp. 549-565
Closed Access | Times Cited: 94
Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents
Leanna Wise, William Stohl
Frontiers in Medicine (2020) Vol. 7
Open Access | Times Cited: 84
Cutaneous Involvement in Systemic Lupus Erythematosus: A Review for the Rheumatologist
Courtney Stull, Grant Sprow, Victoria P. Werth
The Journal of Rheumatology (2022) Vol. 50, Iss. 1, pp. 27-35
Open Access | Times Cited: 45
Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials
Alvaro Gómez, Sandra Jägerback, Christopher Sjöwall, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 2, pp. 338-348
Open Access | Times Cited: 23
Efficacy of lifestyle interventions in the management of systemic lupus erythematosus: a systematic review of the literature
Alexander Tsoi, Alvaro Gómez, Carina Boström, et al.
Rheumatology International (2024) Vol. 44, Iss. 5, pp. 765-778
Open Access | Times Cited: 12
Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations
Myrto Kostopoulou, Chetan Mukhtyar, George Βertsias, et al.
Annals of the Rheumatic Diseases (2024), pp. ard-225319
Open Access | Times Cited: 9
Low disease activity—irrespective of serologic status at baseline—associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study
Antonis Fanouriakis, Christina Adamichou, Sofia Koutsoviti, et al.
Seminars in Arthritis and Rheumatism (2018) Vol. 48, Iss. 3, pp. 467-474
Closed Access | Times Cited: 73
B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice
Ioannis Parodis, Marit Stockfelt, Christopher Sjöwall
Frontiers in Medicine (2020) Vol. 7
Open Access | Times Cited: 68
Systemic Lupus Erythematosus in Primary Care: An Update and Practical Messages for the General Practitioner
Irini Gergianaki, George Βertsias
Frontiers in Medicine (2018) Vol. 5
Open Access | Times Cited: 63
Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric properties
Elisabetta Chessa, Matteo Piga, Alberto Floris, et al.
Lara D. Veeken (2020) Vol. 59, Iss. 12, pp. 3622-3632
Open Access | Times Cited: 57
Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study
Matteo Piga, Elisabetta Chessa, Eric F. Morand, et al.
The Lancet Rheumatology (2022) Vol. 4, Iss. 6, pp. e441-e449
Open Access | Times Cited: 31
Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study
Myrto Nikoloudaki, Dionysis Nikolopoulos, Sofia Koutsoviti, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 19
B-Cell Maturation Antigen (BCMA) as a Biomarker and Potential Treatment Target in Systemic Lupus Erythematosus
J. M. Martin, Qingyu Cheng, Sarah Laurent, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 19, pp. 10845-10845
Open Access | Times Cited: 6
Changing paradigms in the treatment of systemic lupus erythematosus
Antonis Fanouriakis, George Βertsias
Lupus Science & Medicine (2019) Vol. 6, Iss. 1, pp. e000310-e000310
Open Access | Times Cited: 49
Page 1 - Next Page

Scroll to top